2 results match your criteria: "MS Centre University of Catania[Affiliation]"
Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience.
J Neurol
February 2019
Department "G.F. Ingrassia", MS centre University of Catania, Catania, Italy.
Background: Teriflunomide (TRF) and Dimethyl fumarate (DMF) are licensed drugs for relapsing-remitting Multiple Sclerosis (RRMS).
Objectives: We aimed to compare the rate and the time to discontinuation among persons with RRMS (pwRRMS), newly treated with TRF and DMF.
Materials And Methods: A retrospective study on prospectively collected data was performed in nine tertiary MS centers, in Italy.
Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience.
Mult Scler Relat Disord
January 2019
Department "G.F. Ingrassia", MS Centre University of Catania, Policlinico G. Rodolico, V. Santa Sofia 78, Catania 95123, Italy.
Background: Rituximab (RTX), a monoclonal antibody targeting the CD20+ B lymphocytes, deserves major attention as therapeutic option in the treatment of demyelinating disorders of the central nervous system (DDCNS). We reported our clinical experience with the use of RTX in terms of efficacy and safety in persons suffering from DDCNS.
Methods: An Italian single-center observational analysis of patients who underwent RTX treatment between 2011 and 2017 was performed at MS center of Catania, Italy.